Finding Cures Together: The Dream Team for Blood Cancer Research

Updated: Sep 28, 2018

CHICAGO – April 15, 2018 -- Stand Up To Cancer announced a $10 million award to a Stand Up To Cancer Dream Team focused on revolutionizing the treatment of multiple myeloma, an incurable blood cancer of plasma cells, through early detection of precursor conditions before they turn into full-blown disease.

The SU2C Multiple Myeloma Dream Team will be led by Irene Ghobrial, MD, associate professor of medicine at Dana-Farber Cancer Institute (DFCI) in Boston and co-director of the Center for the Prevention of Progression of Blood Cancers at DFCI, with Ivan M. Borrello, MD, associate professor of oncology at Johns Hopkins University School of Medicine and director of the Cell Therapy and GMP Biologics Core at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, as co-leader.

“We tell people with precursor conditions that we will ‘watch and wait’ until it turns into multiple myeloma, with multiple tumors that can potentially cause organ damage,” Dr. Ghobrial said. “That’s like telling people with breast cancer or colon cancer that we are not going to do anything until the cancer metastasizes throughout the body.” +read more




Irene Ghobrial, MD

Recent Posts

See All

Honoring a decade of Standing Up To Cancer

On September 7, Stand Up To Cancer’s (SU2C) telecast shared inspiring stories of hope, perseverance, and groundbreaking cancer research to a worldwide audience. +read more

DFCI Logo Lens Stacked PNG_edited.png
CPOP_R02.png

© 2018 Dana-Farber Cancer Institute |  Terms of Use  |   Privacy Policy